NCT05644600 - A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 26, 2023

Primary Completion Date

July 17, 2023

Study Completion Date

July 17, 2023

Conditions

Healthy Subjects

Interventions

DRUG

Nintedanib

The subjects will be administered Nintedanib soft capsules single oral dose in the morning of Day 1 in fasted state.

DRUG

AZD5055

The subjects will be administered AZD5055 as single oral dose on Day 1 in the fasted state.

Trial Locations (1)

Research Site, Glendale